BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
HLX43: trial readouts and FDA decisions
4 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Shanghai Henlius Biotech. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-22 est. | P2 | Shanghai Henlius Biotech | NCT06839066 A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy | Nasopharyngeal Carcinoma (NPC) | recruiting | 70 |
| 2026-12-30 est. | P2 | Shanghai Henlius Biotech | NCT07106892 Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer | Colorectal Cancer (CRC) | recruiting | 60 |
| 2026-12-30 est. | P2 | Shanghai Henlius Biotech | NCT07459738 A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Ca | Hormone Receptor Positive HER-2 Negative Breast Cancer | not yet recruiting | 60 |
| 2026-12-31 est. | P2 | Shanghai Henlius Biotech | NCT06769152 A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors | Cervical Cancer; Ovarian Cancer | recruiting | 190 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-31 est. | P2 | Shanghai Henlius Biotech | NCT06769113 A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy | Esophageal Cancer | recruiting | 102 |
| 2026-10-31 est. | P2 | Shanghai Henlius Biotech | NCT06742892 A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy | Carcinoma, Hepatocellular | recruiting | 90 |
| 2026-10-30 est. | P1/P2 | Shanghai Henlius Biotech | NCT06848699 A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors | Solid Tumor Cancer; Non Small Cell Lung Cancer | recruiting | 105 |
| 2026-07-10 est. | P2 | Shanghai Henlius Biotech | NCT07269782 A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC | Non Small Cell Lung Cancer | recruiting | 60 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.